⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14042845 | 0.78 | — | — | |
| SCHEMBL9985512 | 0.77 | L3MBTL1 (0.62) | — | |
| SCHEMBL9986002 | 0.77 | L3MBTL1 (0.79) | — | |
| SCHEMBL17030545 | 0.74 | — | — | |
| SCHEMBL3114690 | 0.72 | — | — | |
| SCHEMBL253271 | 0.72 | — | — | |
| SCHEMBL3099671 | 0.72 | — | — | |
| SCHEMBL22380610 | 0.72 | — | — | |
| SCHEMBL1097687 | 0.72 | — | — | |
| SCHEMBL362769 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20100105689-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2125790-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008087178-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |